A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) (Also Known as Ledderhose Disease)
Latest Information Update: 21 Aug 2026
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Fibroma
- Focus Registrational; Therapeutic Use
- Acronyms STRIDE
- Sponsors Endo Pharmaceuticals
Most Recent Events
- 11 Aug 2026 According to a Keenova Therapeutics media release, sBLA Submission is planned in Fourth Quarter 2026.
- 13 Jul 2026 Status changed from active, no longer recruiting to completed.
- 08 Jul 2026 Results presented in the Keenova Therapeutics media release.